Literature DB >> 16475713

Sex chromosome abnormalities in bladder cancer: Y polysomies are linked to PT1-grade III transitional cell carcinoma.

Anna D Panani1, Charis Roussos.   

Abstract

BACKGROUND: Bladder cancer is a heterogeneous group of tumors from both the biological and clinical points of view. Conventional cytogenetics and molecular genetic techniques have shown non-random aberrations in bladder cancer, while certain chromosomal changes have been found to be highly correlated with tumor grade or stage. The aim of this study was to evaluate, by fluorescence in situ hybridization (FISH), the numerical aberrations of chromosomes X and Y in bladder cancer, comparing the incidence of nuclei with aneusomies in different grades or histological stages of the tumors.
MATERIALS AND METHODS: The FISH technique, using DNA probes specific for chromosomes X and Y, was applied to 35 male bladder tumor specimens directly processed for cytogenetic study.
RESULTS: Polysomies of chromosome X were observed in 25 out of the 35 cases examined (71.43%), while numerical aberrations of chromosome Y were observed in 22 out of the 35 cases (62.86%). Of those cases with numerical aberrations of chromosome Y, 13 had polysomy (37.14%), while in 9 cases, loss of Y was observed (25.71%). Statistical analysis showed that numerical aberrations on chromosomes X or Y were not linked to histological stage, while a probable correlation was observed between aneusomies X or Y and tumor grade. Comparing the results of PT1-grade III tumors with those of PT1-grade II, statistical analysis showed that aneusomies Y and, especially, polysomy Y were correlated with PT1-grade III tumors, p = 0.023 and p = 0.010, respectively. An uncertain correlation between polysomy X and PT1-grade III tumors was found, p = 0.070.
CONCLUSION: Our results may suggest that the genetic instability associated with PT1-grade III tumors may account for the considerable potential for aggression of these tumors. However, to draw definite conclusions, a large number of cases must be studied.

Entities:  

Mesh:

Year:  2006        PMID: 16475713

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

1.  Canine urothelial carcinoma: genomically aberrant and comparatively relevant.

Authors:  S G Shapiro; S Raghunath; C Williams; A A Motsinger-Reif; J M Cullen; T Liu; D Albertson; M Ruvolo; A Bergstrom Lucas; J Jin; D W Knapp; J D Schiffman; M Breen
Journal:  Chromosome Res       Date:  2015-03-18       Impact factor: 5.239

2.  Y-chromosome loss is frequent in male renal tumors.

Authors:  Franziska Büscheck; Christoph Fraune; Seyedehmina Garmestani; Ronald Simon; Martina Kluth; Claudia Hube-Magg; Kathrin Ketterer; Christian Eichelberg; Doris Höflmayer; Frank Jacobsen; Corinna Wittmer; Waldemar Wilczak; Guido Sauter; Margit Fisch; Till Eichenauer; Michael Rink
Journal:  Ann Transl Med       Date:  2021-02

3.  Clinical impact of copy number variation changes in bladder cancer samples.

Authors:  Victoria Spasova; Boris Mladenov; Simeon Rangelov; Zora Hammoudeh; Desislava Nesheva; Dimitar Serbezov; Rada Staneva; Savina Hadjidekova; Mihail Ganev; Lubomir Balabanski; Radoslava Vazharova; Chavdar Slavov; Draga Toncheva; Olga Antonova
Journal:  Exp Ther Med       Date:  2021-06-24       Impact factor: 2.447

4.  Chromosomal imbalances in human bladder urothelial carcinoma: similarities and differences between biopsy samples and cancer stem-like cells.

Authors:  Donatella Conconi; Elena Panzeri; Serena Redaelli; Giorgio Bovo; Paolo Viganò; Guido Strada; Leda Dalprà; Angela Bentivegna
Journal:  BMC Cancer       Date:  2014-09-01       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.